Department of Pharmacology, The University of Arizona College of Medicine, Tucson, AZ 85721, USA.
J Neurosci. 2011 May 4;31(18):6646-53. doi: 10.1523/JNEUROSCI.6286-10.2011.
Sensitization of the pain pathway is believed to promote clinical pain disorders. We hypothesized that the persistence of a sensitized state in the spinal dorsal horn might depend on the activity of protein kinase M ζ (PKMζ), an essential mechanism of late long-term potentiation (LTP). To test this hypothesis, we used intraplantar injections of interleukin-6 (IL-6) in mice to elicit a transient allodynic state that endured ∼3 d. After the resolution of IL-6-induced allodynia, a subsequent intraplantar injection of prostaglandin E(2) (PGE(2)) or intrathecal injection of the metabotropic glutamate receptor 1/5 (mGluR1/5) agonist DHPG (dihydroxyphenylglycol) precipitated allodynia and/or nocifensive responses. Intraplantar injection of IL-6 followed immediately by intrathecal injection of a PKMζ inhibitor prevented the expression of subsequent PGE(2)-induced allodynia. Inhibitors of protein translation were effective in preventing PGE(2)-induced allodynia when given immediately after IL-6, but not after the initial allodynia had resolved. In contrast, spinal PKMζ inhibition completely abolished both prolonged allodynia to hindpaw PGE(2) and enhanced nocifensive behaviors evoked by intrathecal mGluR1/5 agonist injection after the resolution of IL-6-induced allodynia. Moreover, spinal PKMζ inhibition prevented the enhanced response to subsequent stimuli following resolution of hypersensitivity induced by plantar incision. The present findings demonstrate that the spinal cord encodes an engram for persistent nociceptive sensitization that is analogous to molecular mechanisms of late LTP and suggest that spinally directed PKMζ inhibitors may offer therapeutic benefit for injury-induced pain states.
痛觉通路的敏化被认为可促进临床疼痛障碍。我们假设,脊髓背角中敏化状态的持续可能依赖于蛋白激酶 M ζ(PKMζ)的活性,PKMζ是晚期长时程增强(LTP)的必要机制。为了检验这一假设,我们在小鼠足底内注射白细胞介素 6(IL-6),诱发短暂的痛觉过敏状态,持续约 3 天。在 IL-6 诱导的痛觉过敏消退后,随后足底内注射前列腺素 E2(PGE2)或鞘内注射代谢型谷氨酸受体 1/5(mGluR1/5)激动剂 DHPG(二羟基苯甘氨酸)会引发痛觉过敏和/或伤害性反应。IL-6 足底内注射后立即鞘内注射 PKMζ 抑制剂可防止随后 PGE2 诱导的痛觉过敏的表达。在 IL-6 后立即给予蛋白质翻译抑制剂可有效预防 PGE2 诱导的痛觉过敏,但在初始痛觉过敏消退后则无效。相比之下,脊髓 PKMζ 抑制完全消除了 IL-6 诱导的痛觉过敏消退后对后足 PGE2 的长期痛觉过敏和鞘内 mGluR1/5 激动剂注射引起的伤害性行为增强。此外,脊髓 PKMζ 抑制可防止在足底切口引起的敏化消退后对后续刺激的增强反应。本研究结果表明,脊髓对持续的伤害性敏化进行编码,类似于晚期 LTP 的分子机制,并提示靶向脊髓的 PKMζ 抑制剂可能为损伤诱导的疼痛状态提供治疗益处。